Advertisement

Impact of Preprocedural B-Type Natriuretic Peptide Levels on the Outcomes After Transcatheter Aortic Valve Implantation

Published:October 03, 2015DOI:https://doi.org/10.1016/j.amjcard.2015.09.031
      There are limited data on the effect of baseline B-type natriuretic peptide (BNP) on the outcome after transcatheter aortic valve implantation (TAVI). We investigated the influence of baseline BNP levels on the short-term and midterm clinical outcomes after TAVI. During a 3-year period, 780 patients with severe aortic stenosis underwent TAVI at our institute and had baseline BNP levels. We compared the high, mid, and low tertiles of BNP levels. TAVI end points, device success, and adverse events were considered according to the Valve Academic Research Consortium 2 definitions. Device success was significantly lower for patients with high BNP (98.1% vs 96.2% vs 91.9% for the low, mid, and high BNP tertiles, respectively; p = 0.003). All-cause mortality up to 30 days was 1.2% (3 of 260) versus 2.3% (6 of 260) versus 5% (13 of 260), respectively (p = 0.03). Six-month mortality rate was 4.1% (10 of 241) for the low BNP tertile, 5% (12 of 239) for the mid BNP tertile, and 17.1% (40 of 234) for the high BNP tertile (p <0.001). In the multivariate model, high tertile of baseline BNP was found to be significantly associated with all-cause mortality (hazard ratio 3.3, 95% confidence interval 1.64 to 6.48; p = 0.001). In conclusion, elevated BNP levels are associated with increased short-term and midterm mortality after TAVI. We recommend measurement of baseline BNP as part of risk stratification models for TAVI.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Daniels L.B.
        • Maisel A.S.
        Natriuretic peptides.
        J Am Coll Cardiol. 2007; 50: 2357-2368
        • Gerber I.L.
        • Stewart R.A.
        • Legget M.E.
        • West T.M.
        • French R.L.
        • Sutton T.M.
        • Yandle T.G.
        • French J.K.
        • Richards A.M.
        • White H.D.
        Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis.
        Circulation. 2003; 107: 1884-1890
        • Parikh V.
        • Kim C.
        • Siegel R.J.
        • Arsanjani R.
        • Rader F.
        Natriuretic peptides for risk stratification of patients with valvular aortic stenosis.
        Circ Heart Fail. 2015; 8: 373-380
        • Bergler-Klein J.
        • Klaar U.
        • Heger M.
        • Rosenhek R.
        • Mundigler G.
        • Gabriel H.
        • Binder T.
        • Pacher R.
        • Maurer G.
        • Baumgartner H.
        Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis.
        Circulation. 2004; 109: 2302-2308
        • Giordana F.
        • D'Ascenzo F.
        • Nijhoff F.
        • Moretti C.
        • D'Amico M.
        • Biondi Zoccai G.
        • Sinning J.M.
        • Nickenig G.
        • Van Mieghem N.M.
        • Chieffo A.
        • Dumonteil N.
        • Tchetche D.
        • Barbash I.M.
        • Waksman R.
        • D'Onofrio A.
        • Lefevre T.
        • Pilgrim T.
        • Amabile N.
        • Codner P.
        • Kornowski R.
        • Yong Z.Y.
        • Baan J.
        • Colombo A.
        • Latib A.
        • Salizzoni S.
        • Omedè P.
        • Conrotto F.
        • La Torre M.
        • Marra S.
        • Rinaldi M.
        • Gaita F.
        Meta-analysis of predictors of all-cause mortality after transcatheter aortic valve implantation.
        Am J Cardiol. 2014; 114: 1447-1455
        • O'Neill B.P.
        • Guerrero M.
        • Thourani V.H.
        • Kodali S.
        • Heldman A.
        • Williams M.
        • Xu K.
        • Pichard A.
        • Mack M.
        • Babaliaros V.
        • Herrmann H.C.
        • Webb J.
        • Douglas P.S.
        • Leon M.B.
        • O'Neill W.W.
        Prognostic value of serial B-type natriuretic peptide measurement in transcatheter aortic valve replacement (from the PARTNER Trial).
        Am J Cardiol. 2015; 115: 1265-1272
        • Kappetein A.P.
        • Head S.J.
        • Généreux P.
        • Piazza N.
        • van Mieghem N.M.
        • Blackstone E.H.
        • Brott T.G.
        • Cohen D.J.
        • Cutlip D.E.
        • van Es G.A.
        • Hahn R.T.
        • Kirtane A.J.
        • Krucoff M.W.
        • Kodali S.
        • Mack M.J.
        • Mehran R.
        • Rodés-Cabau J.
        • Vranckx P.
        • Webb J.G.
        • Windecker S.
        • Serruys P.W.
        • Leon M.B.
        Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document.
        J Am Coll Cardiol. 2012; 60: 1438-1454
        • Maisel A.
        B-type natriuretic peptide measurements in diagnosing congestive heart failure in the dyspneic emergency department patient.
        Rev Cardiovasc Med. 2002; 3: S10-S17
        • Clavel M.A.
        • Malouf J.
        • Michelena H.I.
        • Suri R.M.
        • Jaffe A.S.
        • Mahoney D.W.
        • Enriquez-Sarano M.
        B-type natriuretic peptide clinical activation in aortic stenosis: impact on long-term survival.
        J Am Coll Cardiol. 2014; 63: 2016-2025
        • Pedrazzini G.B.
        • Masson S.
        • Latini R.
        • Klersy C.
        • Rossi M.G.
        • Pasotti E.
        • Faletra F.F.
        • Siclari F.
        • Minervini F.
        • Moccetti T.
        • Auricchio A.
        Comparison of brain natriuretic peptide plasma levels versus logistic EuroSCORE in predicting in-hospital and late postoperative mortality in patients undergoing aortic valve replacement for symptomatic aortic stenosis.
        Am J Cardiol. 2008; 102: 749-754
        • O'Sullivan C.J.
        • Stortecky S.
        • Heg D.
        • Jüni P.
        • Windecker S.
        • Wenaweser P.
        Impact of B-type natriuretic peptide on short-term clinical outcomes following transcatheter aortic valve implantation.
        EuroIntervention. 2015; 10: e1-8
        • López-Otero D.
        • Trillo-Nouche R.
        • Gude F.
        • Cid-Álvarez B.
        • Ocaranza-Sanchez R.
        • Alvarez M.S.
        • Lear P.V.
        • Gonzalez-Juanatey J.R.
        Pro B-type natriuretic peptide plasma value: a new criterion for the prediction of short- and long-term outcomes after transcatheter aortic valve implantation.
        Int J Cardiol. 2013; 168: 1264-1268
        • Kefer J.
        • Beauloye C.
        • Astarci P.
        • Renkin J.
        • Glineur D.
        • Dekleermaeker A.
        • Vanoverschelde J.-L.
        Usefulness of B-type natriuretic peptide to predict outcome of patients treated by transcatheter aortic valve implantation.
        Am J Cardiol. 2010; 106: 1782-1786
        • Ben-Dor I.
        • Minha S.
        • Barbash I.M.
        • Aly O.
        • Dvir D.
        • Deksissa T.
        • Okubagzi P.
        • Torguson R.
        • Lindsay J.
        • Satler L.F.
        • Pichard A.D.
        • Waksman R.
        Correlation of brain natriuretic peptide levels in patients with severe aortic stenosis undergoing operative valve replacement or percutaneous transcatheter intervention with clinical, echocardiographic, and hemodynamic factors and prognosis.
        Am J Cardiol. 2013; 112: 574-579
        • Elhmidi Y.
        • Bleiziffer S.
        • Piazza N.
        • Ruge H.
        • Krane M.
        • Deutsch M.-A.
        • Hettich I.
        • Voss B.
        • Mazzitelli D.
        • Lange R.
        The evolution and prognostic value of N-terminal brain natriuretic peptide in predicting 1-year mortality in patients following transcatheter aortic valve implantation.
        J Invasive Cardiol. 2013; 25: 38-44
        • Stähli B.E.
        • Gebhard C.
        • Saleh L.
        • Falk V.
        • Landmesser U.
        • Nietlispach F.
        • Maisano F.
        • Lüscher T.F.
        • Maier W.
        • Binder R.K.
        N-terminal pro-B-type natriuretic peptide-ratio predicts mortality after transcatheter aortic valve replacement.
        Catheter Cardiovasc Interv. 2015; 85: 1240-1247
        • Ribeiro H.B.
        • Urena M.
        • Le Ven F.
        • Nombela-Franco L.
        • Allende R.
        • Clavel M.-A.
        • Dahou A.
        • Côté M.
        • Laflamme J.
        • Laflamme L.
        • DeLarochellière H.
        • DeLarochellière R.
        • Doyle D.
        • Dumont E.
        • Bergeron S.
        • Pibarot P.
        • Rodés-Cabau J.
        Long-term prognostic value and serial changes of plasma N-terminal prohormone B-type natriuretic peptide in patients undergoing transcatheter aortic valve implantation.
        Am J Cardiol. 2014; 113: 851-859